Interleukin 1 beta (IL1B) promoter polymorphism and cancer risk: evidence from 47 published studies

Interleukin 1 beta (IL-1B) is a pro-inflammatory cytokine against infection, playing an important role in the pathogenesis of cancers. The -31T/C polymorphism of the interleukin 1 beta gene (IL1B) has been implicated in cancer risk through its influence on the IL1B transcription. However, results from studies are conflicting. To clarify the association, a meta-analysis was performed for 11 125 cases and 14 415 controls from 47 published case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. No significant associations were observed for total cancer from all the comparisons. Through the stratified analyses, there was a statistically significant decreased risk of hepatocellular cancer in carriers of the C allele than non-carriers (CC versus TT: OR = 0.87, 95% CI: 0.77-0.98, P-heterogeneity = 0.103; TC versus TT: OR = 0.77, 95% CI: 0.62-0.95, P-heterogeneity = 0.734; TC + CC versus TT: OR = 0.74, 95% CI: 0.61-0.91, P-heterogeneity = 0.472). Similarly, decreased risk was observed for gastric cancer of the C/C genotype compared with the T/T genotype (OR = 0.87, 95% CI: 0.77-0.98, P-heterogeneity = 0.103). Using the recessive model, a significantly decreased risk was observed for gastric cancer (OR = 0.88, 95% CI: 0.80-0.97, P-heterogeneity = 0.158), European population (OR = 0.84, 95% CI: 0.73-0.97, P-heterogeneity = 0.070) and positive infection-matched studies (OR = 0.75, 95% CI: 0.60-0.94, P-heterogeneity = 0.220); however, an increased risk was found for breast cancer (OR = 1.34, 95% CI: 1.18-1.61, P-heterogeneity = 0.116). Although some modest bias could not be eliminated, this meta-analysis suggests that the IL1B -31C allele is a low-penetrance protective factor for the development of cancer, in particular for that associated with infection.